Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status

British Journal of Surgery

Volumn 104, Issue 6, 2017, Pages 760-768

  Odisio, B C ^a   Yamashita, S ^a   Huang, S Y ^a   Harmoush, S ^a   Kopetz, S E ^a   Ahrar, K ^a   Shin Chun, Y ^a   Conrad, C ^a   Aloia, T A ^a   Gupta, S ^a   Hicks, M E ^a   Vauthey, J N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CATHETER ABLATION; COLON TUMOR; COMPUTER ASSISTED SURGERY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HUMAN; LIVER NEOPLASMS; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MUTATION; ONCOGENE RAS; PROCEDURES; RECTUM TUMOR; RETROSPECTIVE STUDY; SECONDARY; SURGICAL MARGIN; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CATHETER ABLATION; COLONIC NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENES, RAS; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MARGINS OF EXCISION; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SURGERY, COMPUTER-ASSISTED; TREATMENT OUTCOME;

EID: 85013926422     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.10490     Document Type: Article

References (27)

1. Solbiati L, Ahmed M, Cova L, Ierace T, Brioschi M, Goldberg SN. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 2012; 265: 958–968.
2. Shady W, Petre EN, Gonen M, Erinjeri JP, Brown KT, Covey AM et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes – a 10-year experience at a single center. Radiology 2016; 278: 601–611.
3. Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 2009; 19: 1206–1213.
4. Hamada A, Yamakado K, Nakatsuka A, Uraki J, Kashima M, Takaki H et al. Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates. Jpn J Radiol 2012; 30: 567–574.
5. Abitabile P, Hartl U, Lange J, Maurer CA. Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol 2007; 33: 67–71.
6. Liang P, Dong B, Yu X, Yang Y, Yu D, Su L et al. Prognostic factors for percutaneous microwave coagulation therapy of hepatic metastases. AJR Am J Roentgenol 2003; 181: 1319–1325.
7. Yan DB, Clingan P, Morris DL. Hepatic cryotherapy and regional chemotherapy with or without resection for liver metastases from colorectal carcinoma: how many are too many? Cancer 2003; 98: 320–330.
8. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 2005; 23: 1358–1364.
9. Sotirchos VS, Petrovic LM, Gönen M, Klimstra DS, Do RK, Petre EN et al. Colorectal cancer liver metastases: biopsy of the ablation zone and margins can be used to predict oncologic outcome. Radiology 2016; 280: 949–959.
10. Wang X, Sofocleous CT, Erinjeri JP, Petre EN, Gonen M, Do KG et al. Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 2013; 36: 166–175.
11. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309–318.
12. Sadot E, Groot Koerkamp B, Leal JN, Shia J, Gonen M, Allen PJ et al. Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? Ann Surg 2015; 262: 476–485.
13. Andreou A, Aloia TA, Brouquet A, Dickson PV, Zimmitti G, Maru DM et al. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 2013; 257: 1079–1088.
14. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011–2019.
15. Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013; 258: 619–626.
16. Taieb J, Zaanan A, Le Malicot K, Julié C, Blons H, Mineur L et al. Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial. JAMA Oncol 2016; 2: 643–653.
17. Brudvik KW, Kopetz SE, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg 2015; 102: 1175–1183.
18. Mise Y, Zimmitti G, Shindoh J, Kopetz S, Loyer EM, Andreou A et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol 2015; 22: 834–842.
19. Schramm K, Krause K, Bittroff-Leben A, Goldin-Lang P, Thiel E, Kreuser ED. Activated K-ras is involved in regulation of integrin expression in human colon carcinoma cells. Int J Cancer 2000; 87: 155–164.
20. Brudvik KW, Mise Y, Chung MH, Chun YS, Kopetz SE, Passot G et al. RAS mutation predicts positive resection margins and narrower resection margins in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol 2016; 23: 2635–2643.
21. Gillams A, Goldberg N, Ahmed M, Bale R, Breen D, Callstrom M et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013. Eur Radiol 2015; 25: 3438–3454.
22. Goldberg SN, Charboneau JW, Dodd GD III, Dupuy DE, Gervais DA, Gillams AR et al. Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology 2003; 228: 335–345.
23. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW et al. Image-guided tumor ablation: standardization of terminology and reporting criteria – a 10-year update. Radiology 2014; 273: 241–260.
24. Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 2012; 30: 4566–4572.
25. Passot G, Chun YS, Kopetz SE, Zorzi D, Brudvik KW, Kim BJ et al. Predictors of safety and efficacy of 2-stage hepatectomy for bilateral colorectal liver metastases. J Am Coll Surg 2016; 223: 99–108.
26. Leung U, Kuk D, D'Angelica MI, Kingham TP, Allen PJ, DeMatteo RP et al. Long-term outcomes following microwave ablation for liver malignancies. Br J Surg 2015; 102: 85–91.
27. Cucchetti A, Ferrero A, Cescon M, Donadon M, Russolillo N, Ercolani G et al. Cure model survival analysis after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2015; 22: 1908–1914.